Suphamai Bunnapradist

List of Publications by Year
in descending order

75 papers	2,625 citations	279487 23 h-index	189595 50 g-index
75 all docs	75 docs citations	75 times ranked	3233 citing authors

#	Article	IF	Citations
1	Kidney utilization and outcomes of liver transplant recipients who were listed for kidney after liver transplant after the implementation of safety net policy. Clinical Transplantation, 2022, 36, e14522.	0.8	8
2	Subclinical non-HLA AMR detection and monitoring with surveillance dd-cfDNA in a kidney transplant recipient. Transplantation Reports, 2022, 7, 100092.	0.3	1
3	T cell senescence and impaired CMV-specific response are associated with infection risk in kidney transplant recipients. Human Immunology, 2022, 83, 273-280.	1.2	7
4	Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients. Transplant Infectious Disease, 2021, 23, e13457.	0.7	5
5	Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial. Annals of Transplantation, 2021, 26, e929535.	0.5	5
6	Impact of donor obesity on allograft outcomes after kidney transplantation adjusted for kidney donor profile index â€“ a national cohort study. Transplant International, 2021, 34, 681-688.	0.8	0
7	Leukocyte transcriptome indicators of development of infection in kidney transplant recipients. Clinical Transplantation, 2021, 35, e14252.	0.8	1
8	Extremely High Cell-free DNA Levels Observed in Renal Allograft Patient With SARS-CoV-2 Infection. Transplantation Direct, 2021, 7, e691.	0.8	6
9	Using both the Fraction and Quantity of Donor-Derived Cell-Free DNA to Detect Kidney Allograft Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 2439-2441.	3.0	15
10	Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. American Journal of Transplantation, 2021, 21, 3811.	2.6	4
11	Single center experience comparing two clinically available donor derived cell free DNA tests and review of literature. Transplantation Reports, 2021, 6, 100079.	0.3	2
12	Association between ethnicity and kidney transplant waitlist outcomes beyond estimated postâ€transplant survival score. Transplant International, 2021, 34, 1837-1844.	0.8	3
13	Outcomes of small pediatric donor kidney transplants according to donor weight. Transplant International, 2021, 34, 2403-2412.	0.8	1
14	Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1175-1186.	1.5	3
15	NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant. JCI Insight, 2021, 6, .	2.3	8
16	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2021, 32, 2973-2974.	3.0	0
17	Acute and Chronic Changes in Gene Expression After CMV DNAemia in Kidney Transplant Recipients. Frontiers in Immunology, 2021, 12, 750659.	2.2	6
18	Listing Malignant Melanoma Patients for Renal Transplantation. Transplantation Proceedings, 2020, 52, 3033-3037.	0.3	2

#	Article	IF	Citations
19	Spectrum of Coronavirus Disease 2019 Outcomes in Kidney Transplant Recipients: A Single-Center Experience. Transplantation Proceedings, 2020, 52, 2654-2658.	0.3	11
20	Time to second kidney transplantation in young adults after failed pediatric kidney transplant. Pediatric Transplantation, 2020, 24, e13800.	0.5	4
21	Evaluation of Renal Disease in Patients With Cirrhosis. Journal of Clinical Gastroenterology, 2020, 54, 314-321.	1.1	5
22	DNA Methylation Age Is More Closely Associated With Infection Risk Than Chronological Age in Kidney Transplant Recipients. Transplantation Direct, 2020, 6, e576.	0.8	9
23	Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. Annals of Transplantation, 2020, 25, e923278.	0.5	6
24	BK Viremia Exacerbation With Adalimumab Coadministration. Transplantation Direct, 2020, 6, e557.	0.8	2
25	Cutaneous Fungal Masses From Prior Environmental Injury Following Kidney Transplant: A Case Report. Transplantation Proceedings, 2019, 51, 3087-3091.	0.3	1
26	Factors predicting kidney delayed graft function among recipients of simultaneous liverâ€kidney transplantation: A singleâ€center experience. Clinical Transplantation, 2019, 33, e13569.	0.8	8
27	Current Status of Simultaneous Liverâ€Kidney Transplantation in the United States. Liver Transplantation, 2019, 25, 797-806.	1.3	25
28	Allocation of the Highest Quality Kidneys and Transplant Outcomes Under the New Kidney Allocation System. American Journal of Kidney Diseases, 2019, 73, 605-614.	2.1	24
29	Differences in Gene Expression in Older Compared With Younger Kidney Transplant Recipients. Transplantation Direct, 2019, 5, e436.	0.8	12
30	Combined Dualâ€Kidney Liver Transplantation in the United States: A Review of United Network for Organ Sharing/Organ Procurement and Transplantation Network Data Between 2002 and 2012. Liver Transplantation, 2018, 24, 1570-1577.	1.3	7
31	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. American Journal of Medicine, 2018, 131, 165-172.	0.6	33
32	629. Blood Transcriptome Variations Predict Infection and Rejection in the Older Kidney Transplant Recipient. Open Forum Infectious Diseases, 2018, 5, S229-S229.	0.4	0
33	Screening Coccidioides serology in kidney transplant recipients: A 10â€year crossâ€sectional analysis. Transplant Infectious Disease, 2018, 20, e12932.	0.7	10
34	Cell-Free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2017, 28, 2221-2232.	3.0	365
35	Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma. American Journal of Kidney Diseases, 2017, 69, 701-704.	2.1	29
36	Marginal quality kidneys for simultaneous liverâ€kidney transplantation: To pass or double down?. Liver Transplantation, 2017, 23, 7-8.	1.3	2

#	Article	IF	Citations
37	Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports. Transplantation Direct, 2017, 3, e200.	0.8	16
38	Association of Pretransplant Skin Cancer With Posttransplant Malignancy, Graft Failure and Death in Kidney Transplant Recipients. Transplantation, 2017, 101, 1303-1309.	0.5	26
39	Effect of diabetes and acute rejection on liver transplant outcomes: An analysis of the organ procurement and transplantation network/united network for organ sharing database. Liver Transplantation, 2016, 22, 796-804.	1.3	19
40	Effects of acute rejection vs newâ€onset diabetes after transplant on transplant outcomes in pediatric kidney recipients: analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Pediatric Transplantation, 2016, 20, 952-957.	0.5	4
41	<scp>LCPT</scp>onceâ€daily extendedâ€release tacrolimus tablets versus twiceâ€daily capsules: a pooled analysis of two phase 3 trials in importantde novoand stable kidney transplant recipient subgroups. Transplant International, 2016, 29, 603-611.	0.8	25
42	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal of Kidney Diseases, 2016, 67, 648-659.	2.1	78
43	Pretransplant Malignancy as a Risk Factor for Posttransplant Malignancy After Heart Transplantation. Transplantation, 2015, 99, 345-350.	0.5	21
44	Kidney retransplantation for BK virus nephropathy with active viremia without allograft nephrectomy. Journal of Nephrology, 2015, 28, 773-777.	0.9	17
45	Adverse Outcomes of Tacrolimus Withdrawal in Immuneâ€“Quiescent Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2015, 26, 3114-3122.	3.0	172
46	Recent Trends in Kidney Transplant in the United States. Clinical Transplants, 2015, 31, 1-13.	0.2	1
47	Impact of Diabetes Mellitus on Survival Outcome of Lung Transplant Recipients: An Analysis of OPTN/UNOS Data. Clinical Transplants, 2015, 31, 43-55.	0.2	2
48	Changes in the Small Bowel of Symptomatic Kidney Transplant Recipients Converted from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium. American Journal of Nephrology, 2014, 40, 184-190.	1.4	11
49	Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients?. Nephrology Dialysis Transplantation, 2014, 29, 1247-1252.	0.4	10
50	Renal Dysfunction in End-Stage Liver Disease and Postâ€“Liver Transplant. Clinics in Liver Disease, 2014, 18, 543-560.	1.0	25
51	Bone and mineral disorders after kidney transplantation: Therapeutic strategies. Transplantation Reviews, 2014, 28, 56-62.	1.2	25
52	Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT). Transplantation, 2013, 96, 191-197.	0.5	81
53	Management of mineral and bone disorder after kidney transplantation. Current Opinion in Nephrology and Hypertension, 2012, 21, 389-403.	1.0	49
54	Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease. Kidney Research and Clinical Practice, 2012, 31, 12-25.	0.9	7

#	Article	IF	Citations
55	Management of Renal Dysfunction in Patients Receiving a Liver Transplant. Clinics in Liver Disease, 2011, 15, 807-820.	1.0	9
56	Risk Factors for Development of New-Onset Diabetes Mellitus in Pediatric Renal Transplant Recipients: An Analysis of the OPTN/UNOS Database. Transplantation, 2010, 89, 434-439.	0.5	20
57	Associations of Pretransplant Diabetes Mellitus, New-Onset Diabetes After Transplant, and Acute Rejection With Transplant Outcomes: An Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) Database. American Journal of Kidney Diseases, 2010, 56, 1127-1139.	2.1	114
58	Pretransplant risk factors for new-onset diabetes mellitus after transplant in pediatric liver transplant recipients. Liver Transplantation, 2010, 16, 1249-1256.	1.3	31
59	Risk Factors for New-Onset Diabetes Mellitus in Adult Liver Transplant Recipients, an Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing Database. Transplantation, 2010, 89, 1134-1140.	0.5	126
60	Impact of gastrointestinalâ€related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clinical Transplantation, 2008, 22, 815-821.	0.8	51
61	Incidence and Risk Factors for Diarrhea Following Kidney Transplantation and Association With Graft Loss and Mortality. American Journal of Kidney Diseases, 2008, 51, 478-486.	2.1	140
62	Outcomes of Dual Adult Kidney Transplants in the United States: An Analysis of the OPTN/UNOS Database. Transplantation, 2008, 85, 62-68.	0.5	85
63	Minimizing ciclosporin in renal transplant recipients on daclizumab, mycophenolate and steroids. Nature Clinical Practice Nephrology, 2007, 3, 426-427.	2.0	1
64	Evaluation of Adult Kidney Transplant Candidates. American Journal of Kidney Diseases, 2007, 50, 890-898.	2.1	92
65	Risk Factors for Development of New-Onset Diabetes Mellitus After Kidney Transplantation. Transplantation, 2006, 82, 1673-1676.	0.5	142
66	Mycophenolate Mofetil Dose Reductions and Discontinuations after Gastrointestinal Complications Are Associated with Renal Transplant Graft Failure. Transplantation, 2006, 82, 102-107.	0.5	142
67	Treatment of HCV infection in patients with renal failure. Current Hepatitis Reports, 2006, 5, 101-107.	0.3	0
68	Does plasmapheresis desensitize kidney transplant recipients more effectively than high-dose immunoglobulin?. Nature Clinical Practice Nephrology, 2006, 2, 484-485.	2.0	0
69	Hepatitis C Virus Antibody Status and Survival After Renal Transplantation: Meta-Analysis of Observational Studies. American Journal of Transplantation, 2005, 5, 1452-1461.	2.6	235
70	Dual Kidneys from Marginal Adult Donors as a Source For Cadaveric Renal Transplantation in the United States. Journal of the American Society of Nephrology: JASN, 2003, 14, 1031-1036.	3.0	66
71	Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis of the UNOS Database. Journal of the American Society of Nephrology: JASN, 2003, 14, 208-213.	3.0	108
72	GRAFT SURVIVAL FOLLOWING LIVING-DONOR RENAL TRANSPLANTATION. Transplantation, 2003, 76, 10-15.	0.5	38

#	Article	IF	Citations
73	Multivariate analyses of antibody induction therapies. Clinical Transplants, 2003, , 405-17.	0.2	2
74	Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation, 2002, 74, 1648-1651.	0.5	4
75	Patterns of administration of antibody induction therapy and their associated outcomes. Clinical Transplants, 2002, , 351-8.	0.2	0